Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation
Early treatment of multiple myeloma at disease recurrence detection hints at possible survival benefit, needing randomized trial confirmation.
This small retrospective study (n=42) from Sun Yat-sen University suggests that treating multiple myeloma at MRD progression onset (before clinical relapse) may confer survival benefit, providing preliminary data to inform future randomized trials. The small sample, non-randomized design, and unmeasured confounders mean these findings are hypothesis-generating only and should not change practice.
What the study was
- Study design
- Retrospective cohort
- Population
- Newly diagnosed MM patients developing MRD progression after ASCT; single-center, Sun Yat-sen University
- Sample size
- 42
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Medicine
Why it surfaced
Addresses clinically important question of MRD-guided intervention in MM. EI group n=9 is very small, severely limiting conclusions. Authors acknowledge limitations. Useful for hypothesis generation toward prospective randomized trial design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.